

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

BD Biosciences: FACS Celesta Flow Cytometer

RRID:SCR_019597

Type: Tool

Proper Citation

BD Biosciences: FACS Celesta Flow Cytometer (RRID:SCR_019597)

Resource Information

URL: <https://www.bdbiosciences.com/en-us/instruments/research-instruments/research-cell-analyzers/facscelesta>

Proper Citation: BD Biosciences: FACS Celesta Flow Cytometer (RRID:SCR_019597)

Description: BD FACSCelesta flow cytometer makes multicolor flow cytometry more accessible and enables insights in cell analysis.

Resource Type: instrument resource

Keywords: BD Biosciences, Flow Cytometer, Instrument Equipment, USEdit

Availability: Commercially available

Resource Name: BD Biosciences: FACS Celesta Flow Cytometer

Resource ID: SCR_019597

Alternate IDs: Model_Number_Celesta

Record Creation Time: 20220129T080346+0000

Record Last Update: 20260801T190629+0000

Ratings and Alerts

No rating or validation information has been found for BD Biosciences: FACS Celesta Flow Cytometer.

No alerts have been found for BD Biosciences: FACS Celesta Flow Cytometer.

Data and Source Information

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Shen F, et al. (2025) Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(21), 4543.

Stockmann AP, et al. (2025) DF6215, an ??-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity. *Cell reports. Medicine*, 102518.

Kortleve D, et al. (2024) TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer. *Cancer discovery*, 14(12), 2450.

Yang L, et al. (2024) Neurons enhance blood-brain barrier function via upregulating claudin-5 and VE-cadherin expression due to glial cell line-derived neurotrophic factor secretion. *eLife*, 13.

Ahn DH, et al. (2024) Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(10), 2039.

Wang H, et al. (2024) Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer. *Med (New York, N.Y.)*, 5(10), 1237.

Lozano-Rabella M, et al. (2023) Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(12), 2250.

Fowler FC, et al. (2022) DNA-PK promotes DNA end resection at DNA double strand breaks in G0 cells. *eLife*, 11.

Zhou Z, et al. (2022) Evaluation of the tumoricidal efficacy of adoptive cell transfer using hepatocellular carcinoma-derived organoids. *Journal of gastrointestinal oncology*, 13(2), 732.

Ren BX, et al. (2022) The antibiotic drug trimethoprim suppresses tumour growth and metastasis via targeting Snail. *British journal of pharmacology*, 179(11), 2659.